PEMETREXED TEVA RTU 25 MGML

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

PEMETREXED

Dostępny od:

ABIC MARKETING LTD, ISRAEL

Kod ATC:

L01BA04

Forma farmaceutyczna:

CONCENTRATE FOR SOLUTION FOR INFUSION

Skład:

PEMETREXED 25 MG / 1 ML

Droga podania:

I.V

Typ recepty:

Required

Wyprodukowano przez:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Dziedzina terapeutyczna:

PEMETREXED

Wskazania:

Pemetrexed Teva RTU in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Pemetrexed Teva RTU in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva RTU is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva RTU is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Data autoryzacji:

2018-01-03